|
[1]
|
Rajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Pattrapornpisut, P., Avila-Casado, C. and Reich, H.N. (2021) IgA Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 78, 429-441. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Gutierrez, E., et al. (2012) Long-Term Outcomes of IgA Nephrop-athy Presenting with Minimal or No Proteinuria. Journal of the American Society of Nephrology, 23, 1753-1760. [Google Scholar] [CrossRef]
|
|
[4]
|
Suzuki, H., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803. [Google Scholar] [CrossRef]
|
|
[5]
|
Li, M., et al. (2020) Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heteroge-neity of Genetic Susceptibility for IgA Nephropathy. Journal of the American Society of Nephrology, 31, 2949- 2963. [Google Scholar] [CrossRef]
|
|
[6]
|
(2021) Kidney Disease: Improving Global Outcomes Glomerular Diseases Work, G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Inter-national, 100, S1-S276.
|
|
[7]
|
Wyatt, R.J., et al. (1998) Epidemiology of IgA Nephropathy in Central and Eastern Ken-tucky for the Period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy Databank Project. Journal of the American Society of Nephrology, 9, 853-858. [Google Scholar] [CrossRef]
|
|
[8]
|
Schena, F.P. (1990) A Retrospective Analysis of the Natural History of Primary IgA Nephropathy Worldwide. The American Journal of Medicine, 89, 209-215. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Shen, P., et al. (2006) Clinicopathological Characteristics and Outcome of Adult Patients with Hematuria and/or Proteinuria Found during Routine Examination. Nephron Clinical Practice, 103, c149-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Li, L.S. and Liu, Z.H. (2004) Epidemiologic Data of Renal Diseases from a Single Unit in China: Analysis Based on 13,519 Renal Biopsies. Kidney International, 66, 920-923. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Woo, K.T., et al. (2010) Global Evolutionary Trend of the Prevalence of Primary Glomerulonephritis over the Past Three Decades. Nephron Clinical Practice, 116, c337-346. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Kiryluk, K., et al. (2014) Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens. Nature Genetics, 46, 1187-1196. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Saka, S., et al. (2015) Genome-Wide Association Study of IgA Nephropathy Using 23465 Microsatellite Markers in a Japanese Population. Journal of Human Genetics, 60, 573-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Feehally, J., et al. (2010) HLA Has Strongest Association with IgA Nephropathy in Genome-Wide Analysis. Journal of the American Society of Nephrology, 21, 1791-1797. [Google Scholar] [CrossRef]
|
|
[15]
|
Li, M., et al. (2015) Identification of New Susceptibility Loci for IgA Nephropathy in Han Chinese. Nature Communications, 6, 7270. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Suzuki, K., et al. (2003) Incidence of Latent Mesangial IgA Deposition in Renal Allograft Donors in Japan. Kidney International, 63, 2286-2294. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Gharavi, A.G., et al. (2008) Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy. Journal of the American Society of Nephrology, 19, 1008-1014. [Google Scholar] [CrossRef]
|
|
[18]
|
Suzuki, H., et al. (2009) Aberrantly Glycosylated IgA1 in IgA Nephropathy Patients Is Recognized by IgG Antibodies with Restricted Heterogeneity. The Journal of Clinical Investiga-tion, 119, 1668-1677. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhang, W. and Lachmann, P.J. (1994) Glycosylation of IgA Is Required for Optimal Activation of the Alternative Complement Pathway by Immune Complexes. Immunology, 81, 137-141.
|
|
[20]
|
Magistroni, R., D’Agati, V.D., Appel, G.B. and Kiryluk, K. (2015) New Developments in the Genetics, Pathogenesis, and Therapy of IgA Nephropathy. Kidney International, 88, 974-989. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Perše, M. and Večerić-Haler, Z. (2019) The Role of IgA in the Pathogen-esis of IgA Nephropathy. International Journal of Molecular Sciences, 20, 6199. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Julian, B.A., et al. (1985) Familial IgA Nephropathy. Evidence of an Inherited Mechanism of Disease. The New England Journal of Medicine, 312, 202-208. [Google Scholar] [CrossRef]
|
|
[23]
|
Scolari, F., et al. (1999) Familial Clustering of IgA Nephropathy: Further Evidence in an Italian Population. American Journal of Kidney Diseases, 33, 857-865. [Google Scholar] [CrossRef]
|
|
[24]
|
Paterson, A.D., et al. (2007) Genome-Wide Linkage Scan of a Large Family with IgA Nephropathy Localizes a Novel Susceptibility Locus to Chromosome 2q36. Journal of the American Society of Nephrology, 18, 2408-2415. [Google Scholar] [CrossRef]
|
|
[25]
|
Karnib, H.H., et al. (2007) Characterization of a Large Lebanese Family Segregating IgA Nephropathy. Nephrology Dialysis Transplantation, 22, 772-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Tsuboi, N., et al. (2011) Discordant Clinicopathological Features in Monozygotic Twins with IgA Nephropathy. Nephrology Dialysis Transplantation, 26, 4146-4148. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Schena, F.P., et al. (1993) Abnormalities of the IgA Immune System in Members of Unrelated Pedigrees from Patients with IgA Nephropathy. Clinical and Experimental Immunology, 92, 139-144. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Kiryluk, K., et al. (2011) Aberrant Glycosylation of IgA1 Is Inherited in both Pediatric IgA Nephropathy and Henoch- Schönlein Purpura Nephritis. Kidney International, 80, 79-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Feehally, J. and Barratt, J. (2015) The Genetics of IgA Nephropa-thy: An Overview from Western Countries. Kidney Diseases (Basel, Switzerland), 1, 33-41. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Coppo, R. (2015) The Intestine-Renal Connection in IgA Nephropathy. Nephrology Dialysis Transplantation, 30, 360-366. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Bunker, J.J. and Ben-delac, A. (2018) IgA Responses to Microbiota. Immunity, 49, 211-224. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Floege, J., Rauen, T. and Tang, S.C.W. (2021) Current Treat-ment of IgA Nephropathy. Seminars in Immunopathology, 43, 717-728. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Russo, D., et al. (2001) Coadministration of Losartan and Enal-april Exerts Additive Antiproteinuric Effect in IgA Nephropathy. American Journal of Kidney Diseases, 38, 18-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Lennartz, D.P., et al. (2020) Single versus Dual Blockade of the Renin-Angiotensin System in Patients with IgA Nephropathy. Journal of Nephrology, 33, 1231-1239. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Heerspink, H.J.L., et al. (2019) Atrasentan and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (SONAR): A Double-Blind, Randomised, Place-bo-Controlled Trial. The Lancet, 393, 1937-1947. [Google Scholar] [CrossRef]
|
|
[36]
|
Kim, S.-G., et al. (2022) FC052: Atrasentan for the Treat-ment of IGA Nephropathy: Interim Results from the Affinity Study. Nephrology Dialysis Transplantation, 37, gfac107.004. [Google Scholar] [CrossRef]
|
|
[37]
|
Heerspink, H.J.L., Kosiborod, M., Inzucchi, S.E. and Cherney, D.Z.I. (2018) Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors. Kidney International, 94, 26-39. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
van Bommel, E.J.M., Muskiet, M.H.A., van Baar, M.J.B., et al. (2020) The Renal Hemodynamic Effects of the SGLT2 Inhibitor Dapagliflozin Are Caused by Post-Glomerular Vas-odilatation Rather than Pre-Glomerular Vasoconstriction in Metformin-Treated Patients with Type 2 Diabetes in the Ran-domized, Double-Blind RED Trial. Kidney International, 97, 202-212. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Wheeler, D.C., et al. (2021) Effects of Dapagliflozin on Major Ad-verse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespec-ified Analysis from the DAPA-CKD Trial. The Lancet. Diabetes and Endocrinology, 9, 22-31. [Google Scholar] [CrossRef]
|
|
[40]
|
Cherney, D.Z.I., et al. (2020) Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial. The Lancet. Diabetes and Endocrinology, 8, 582-593. [Google Scholar] [CrossRef]
|
|
[41]
|
Herrington, W.G., et al. (2022) Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 388, 117-127.
|
|
[42]
|
Rauen, T., et al. (2015) Inten-sive Supportive Care plus Immunosuppression in IgA Nephropathy. The New England Journal of Medicine, 373, 2225-2236. [Google Scholar] [CrossRef]
|
|
[43]
|
Lunde Haaskjold, Y., Rivedal, M., Gjærde Lura, N., Bjorneklett, R. and Knoop, T. (2022) MO268: Use of Corticosteroids in a Norwegian Cohort of Patients with IGA Nephropathy and Rapid Progression to End-Stage Renal Disease. Nephrology Dialysis Transplantation, 37, gfac067.067. [Google Scholar] [CrossRef]
|
|
[44]
|
Fellström, B.C., et al. (2017) Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Place-bo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127. [Google Scholar] [CrossRef]
|
|
[45]
|
Barratt, J., et al. (2022) Results from Part A of the Mul-ti-Center, Double-Blind, Randomized, Placebo-Controlled NefIgArd Trial, Which Evaluated Targeted-Release Formula-tion of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy. Kidney International, 103, 391-402.
|
|
[46]
|
Tang, S.C., et al. (2010) Long-Term Study of Mycophenolate Mofetil Treatment in IgA Nephropathy. Kidney International, 77, 543-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Hou, J.H., et al. (2017) Mycopheno-late Mofetil Combined with Prednisone versus Full-Dose Prednisone in IgA Nephropathy with Active Proliferative Le-sions: A Randomized Controlled Trial. American Journal of Kidney Diseases, 69, 788-795. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Chen, Y., Li, Y., Yang, S., Li, Y. and Liang, M. (2014) Efficacy and Safety of Mycophenolate Mofetil Treatment in IgA Nephropathy: A Systematic Review. BMC Nephrology, 15, 193. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Maes, B.D., et al. (2004) Mycophenolate Mofetil in IgA Nephrop-athy: Results of a 3-Year Prospective Placebo- Controlled Randomized Study. Kidney International, 65, 1842-1849. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Frisch, G., et al. (2005) Mycophenolate Mofetil (MMF) vs Placebo in Patients with Moderately Advanced IgA Nephropathy: A Double-Blind Randomized Controlled Trial. Neph-rology Dialysis Transplantation, 20, 2139-2145. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Le Guern, V. and Guettrot-Imbert, G. (2014) Hydroxychloroquine: A Multifaceted Treatment in Lupus. Presse Medicale (Paris, France: 1983), 43, e167-e180. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Komissarov, K., Nizheharodava, D., Pilotovich, V. and Zafran-skaya, M. (2022) MO220: Comparison of the Effects of Hydroxychloroquine and Glucocorticosteroids on Immunologi-cal Parametrs in Patients with IGA Nephropathy. Nephrology Dialysis Transplantation, 37, gfac067.019. [Google Scholar] [CrossRef]
|
|
[53]
|
Gao, R., Wu, W., Wen, Y. and Li, X. (2017) Hydroxychloroquine Alleviates Persistent Proteinuria in IgA Nephropathy. International Urology and Nephrology, 49, 1233-1241. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Liu, L.J., et al. (2019) Effects of Hydroxychloroquine on Pro-teinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Evans, D.J., et al. (1973) Glomerular Deposition of Properdin in Henoch-Schönlein Syndrome and Idiopathic Focal Nephritis. British Medical Journal, 3, 326-328. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Tomino, Y. (1980) Complement System in IgA Nephropathy. The Tokai Journal of Experimental and Clinical Medicine, 5, 15-22.
|
|
[57]
|
Wang, Z., et al. (2021) Complement Activation Is Associated with Crescents in IgA Nephropathy. Frontiers in Immunology, 12, Article ID: 676919. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Liu, M., et al. (2015) Implication of Urinary Complement Factor H in the Progression of Immunoglobulin A Nephropathy. PLOS ONE, 10, e0126812. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Samy, E., Wax, S., Huard, B., Hess, H. and Schneider, P. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. Inter-national Reviews of Immunology, 36, 3-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Fan, Y., Gao, D. and Zhang, Z. (2022) Telitacicept, A Novel Humanized, Recombinant TACI-Fc Fusion Protein, for the Treatment of Systemic Lupus Erythematosus. Drugs of To-day (Barcelona, Spain: 1998), 58, 23-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Barratt, J., et al. (2022) Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Kidney International Reports, 7, 1831-1841. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Barratt, J., et al. (2022) FC051: Atacicept Reduces Serum ANTI-GD-IGA1 Levels in IgAN Patients. Nephrology Dialysis Transplantation, 37, gfac107.003. [Google Scholar] [CrossRef]
|
|
[63]
|
Barratt, J., et al. (2022) MO212: Updated Interim Results of a Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IGA Nephropathy. Nephrology Dialysis Transplantation, 37, gfac067.011. [Google Scholar] [CrossRef]
|